The company’s surgical specialties business quarterly revenues reached $8.5 million, an 18 percent increase, while its bone graft substitutes and general orthopedic business quarterly revenues reached $7.0 million, a 12 percent increase. RTI Biologics’ sports medicine business line also achieved $13.3 million, a 10 percent increase over the second quarter of 2011.
More Articles on Orthopedic Devices:
Global Spinal Devices and Biologics Market to Grow 6.9% Annually
DePuy Synthes Spine Systems Receive FDA Approval to Treat Scoliosis
Symmetry Medical Announces 2Q Revenue of $102.3M, 8% Increase
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
